New application of partial metabolite of pentapeptide in preparation of myocardial ischemia resistant product

Abstract

The invention relates to the technical field of biomedicine, and in particular relates to a new application of partial metabolite of pentapeptide in preparation of a myocardial ischemia resistant product. The amino acid sequence of the small peptide is shown as Seq No.2, No.3, No.4, No.5, No.6 and No.7. Through pharmacological experiments of acute rat myocardial ischemia and damage models, the small peptide and the metabolite thereof can remarkably reduce the range of rat myocardial damage and myocardial infarction caused by myocardial ischemia, reduce the content of lactic dehydrogenase and creatine kinase in myocardial ischemia rat serum and have the function of preventing and treating the myocardial ischemia, so the small peptide and the metabolite thereof can be used for preparing a medicament for preventing and treating the myocardial ischemia.

Description

technical field [0001] The present invention relates to the technical fields of medicine, food, reagents, etc., specifically to the new use of a partial metabolite of a small peptide in biomedical technology, and more specifically to a pentapeptide that inhibits the movement of monocytes The novel use of some in vivo metabolites of factors for the preparation of anti-myocardial ischemia products, and more specifically an application involving six small peptides in the preparation of anti-myocardial ischemia products. Background technique [0002] With the improvement of people's living standards, cardiovascular disease has become a major disease that endangers human health. Epidemiological surveys in recent years have shown that the morbidity and mortality of cardiovascular diseases in the Chinese population have continued to rise, and the age of onset has gradually decreased. , has become a serious threat to human health, affecting the quality of life of common diseases, fr...

AI Technical Summary

Problems solved by technology

[0078] However, through literature search, etc., up to now, no report has been found that the partial metabolites of the pentapeptide are used for the preparation of anti-myocardial ischemia products, etc.